Aclaris Therapeutics (8AT) AI Stock Analysis

Aclaris Therapeutics

(Frankfurt:8AT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

ATI-052 clinical validationPositive Phase 1b proof-of-concept results provide clinical validation for ATI-052 across two immune-inflammatory diseases. Rapid responses, durable improvements and no observed conjunctivitis support advancing the asset into a focused Phase 2b program and may strengthen its partnering potential.

Negative Factors

Persistent cash burnAclaris is consuming substantial cash while its programs remain in development, making continued external funding important for operating continuity. Even though cash flow improved versus the prior year, materially negative free cash flow can constrain trial expansion and future capital allocation.

Aclaris Therapeutics (8AT) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 584.38M
Dividend Yield: ―
Average Volume (3M): 592
Price to Earnings (P/E): -6.8
Beta (1Y): 0.55
Revenue Growth: -54.68%
EPS Growth: 60.64%
Country: Germany
Employees: 71
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Aclaris Therapeutics Business Overview & Revenue Model

Company Description

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are...

Aclaris Therapeutics Earnings Call Summary

Earnings Call Date:May 06, 2024(Q1-2024)|% Change Since:191.37%|Next Earnings Date:Nov 10, 2026

Earnings Call SentimentNeutral

The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.

Positive Updates

Strong Financial Position

Aclaris ended the first quarter with $161 million in cash, cash equivalents, and marketable securities, with no outstanding debt. This positions the company well financially for upcoming initiatives.

Negative Updates

Decreased Cash Reserves

Cash reserves decreased from $182 million at year-end to $161 million at the end of Q1, partly due to nonrecurring payments related to discontinued programs and severance.

Company Guidance

During the Aclaris Therapeutics Q1 2024 earnings call, several key metrics and strategic updates were provided. The company ended the first quarter with cash, cash equivalents, and marketable securities totaling $161 million, down from $182 million at the end of the previous year. Approximately $14 million of the expenditures in the first quarter were related to nonrecurring payments. Aclaris has decided to advance ATI-2138, their oral small molecule ITK JAK3 inhibitor, into a Phase II proof-of-concept study targeting atopic dermatitis. The study is designed as an open-label trial involving 15 patients over 12 weeks, with a focus on safety, pharmacokinetics (PK), and early efficacy signals. Joseph Monahan highlighted that ATI-2138 is 44.4 times more potent than ritlecitinib in blocking ITK-dependent cytokine production and 5.4 times more potent in JAK3-dependent readouts. Financially, Aclaris is committed to maintaining a strong balance sheet with ongoing cost containment initiatives and exploring business development opportunities to source nondilutive capital.

Aclaris Therapeutics Risk Analysis

Aclaris Therapeutics disclosed 72 risk factors in its most recent earnings report. Aclaris Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.The rapid advancement of artificial intelligence and computational drug discovery technologies could make our KINect platform and discovery approaches less competitive or obsolete, and our failure to successfully adopt and integrate artificial intelligence technologies could put us at a competitive disadvantage.Q4, 2025

Aclaris Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:8AT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	75Outperform	$958.46M	2.90	96.49%	―	3.31%	221.64%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDXG	49Neutral	$566.19M	-29.96	-8.29%	―	-22.80%	-147.20%
OMER	48Neutral	$1.33B	9.65	-109.40%	―	―	―
REPL	48Neutral	$1.67B	-6.31	-157.78%	―	―	19.12%
GALT	44Neutral	$334.82M	-7.78	21.48%	―	―	33.25%

* Healthcare Sector Average

Performance Comparison

DE:8AT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:8AT	Aclaris Therapeutics Inc.	3.44	1.23	55.77%
OMER	Omeros Corporation	18.44	11.27	157.18%
RIGL	Rigel Pharmaceuticals	51.31	20.66	67.41%
GALT	Galectin Therapeutics (GALT)	3.32	-2.68	-44.67%
MDXG	MiMedx Group Inc.	3.88	-3.64	-48.40%
REPL	Replimune Group	17.61	8.30	89.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Aclaris Therapeutics AI Stock Analysis